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Thalassemias are a group of congenital anemias associated with defective synthesis of one or more of the globin subunits of the normal human hemoglobin. This results in 
excess production of the other chain which damages the red cell 
membrane and causes hemolytic anemia [1]. Hepatic dysfunction 
is a frequent manifestation in thalassemic patients receiving 
multiple blood transfusions (BTs) as a part of treatment. The liver 
plays a central role in iron homeostasis. Iron is released from 
hemolyzed and transfused red cells. This excess iron is initially 
confined to the Kupffer cells, but when multiple transfusions 
cause massive iron overload, spillover to hepatic parenchyma 
cells quickly occurs, with the risk of late development of fibrosis 
and cirrhosis [2].
Liver dysfunction resulting from ongoing hemolysis, excess 
iron deposition, and/or chronic viral infections is a major cause 
of morbidity and mortality among thalassemic children on 
BT therapy. Excess iron is toxic to all body tissues, including 
liver, where it causes irreversible damage, such as fibrosis and 
liver cirrhosis [3]. Regular BT improves the overall survival of 
thalassemic patients, but it carries a risk of infection with blood-
borne viruses such as hepatitis B virus (HBV) and hepatitis C 
virus (HCV) which can cause hepatic dysfunction [4].
When serum ferritin level exceeds 1000 ng/ml and the 
numbers of transfusions are >30, derangement in liver enzymes 
starts occurring in the thalassemia patients [5]. Although with 
regular BTs and iron chelation therapy, these patients can survive 
beyond the fifth decade of life [6], liver disease still remains an 
important cause of morbidity and mortality among these patients. 
The aim of this study was to study the liver function profile in 
thalassemic children and its correlation with the age of initiation 
of transfusion therapy.
MATERIALS AND METHODS
This cross-sectional study was done among thalassemic patients 
in the age group of 1–18 years visiting a tertiary care hospital of 
ABSTRACT
Background: Hepatic dysfunction is a frequent manifestation in thalassemic patients receiving multiple blood transfusions (BTs) 
as a part of treatment. Objective: The objective of the study was to study the liver function profile in thalassemic children and 
its correlation with the age of initiation of transfusion therapy. Materials and Methods: This cross-sectional study was done 
among 32 thalassemic patients in the age group of 1–18 years visiting a tertiary care hospital regularly for BTs at the Department 
of Pediatrics at the tertiary hospital of North India. Liver function tests (LFTs) were done in all thalassemic patients included total 
bilirubin, liver enzymes (serum glutamic oxaloacetic transaminase [SGOT], serum glutamic pyruvic transaminase [SGPT], and 
alkaline phosphatase [ALP]), total protein, serum albumin, serum ferritin, hepatitis B surface antigen (HBsAg), and anti-hepatitis 
C virus. The age of initiation of BT was also recorded. Derangement in LFTs and correlation between the age of initiation of 
transfusion therapy and derangement of liver function were studied. Results: Out of 32 patients, only 7 (21.87%) had normal LFT 
values. A total of 17 (53.12%) had increased SGOT, 15 (46.87%) had increased SGPT, and 25 (78.12%) had increased bilirubin 
levels. Total protein and serum albumin were below normal in 5 (15.65%) and 3 (9.3%) patients, respectively. ALP was increased 
in 24 (75%) patients. Majority of the patients (43.75%) had serum ferritin between 2000 and 2999 ng/ml. Only two patients had 
significantly deranged LFTs. No patient was positive for HBsAg. However, we did not find a significant correlation between age 
of initiation of transfusion therapy and derangement of liver enzymes in these patients. Conclusion: If thalassemic patients are 
given properly tested blood and regular chelation therapy, liver function remains normal. Immunization against hepatitis B and 
testing of blood bags is recommended. It is also recommended that LFT should be done regularly at 3 months interval to detect any 
abnormality.
Key words: Chelation, Ferritin, Hepatitis, Thalassemia
Original Article
Liver function profile in thalassemic children receiving multiple blood 
transfusions
Prashant Srivastava1, Ruchi Mishra2, A P Dubey3, Jyoti Bagla4
From 1Post Graduate Resident, 2Assistant Professor, 3Professor, 4Professor and Head, Department of Pediatrics, ESI Post Graduate Institute of 
Medical Sciences and Research, Basaidarapur, New Delhi, India
Correspondence to: Ruchi Mishra, Department of Pediatrics, ESI Post Graduate Institute of Medical Sciences and Research, 
Basaidarapur, New Delhi, India. E-mail: mishraruchi11@gmail.com
Received - 24 October 2019 Initial Review - 05 November 2019 Accepted - 14 November 2019
Srivastava et al. Liver function profile in thalassemic children 
Online First Indian J Child Health 2
North India for BTs at the department of pediatrics. The study was 
approved by the Institutional Ethics Committee. All patients were 
enrolled for this study after informed consent from their parents 
and assent from children above the age of 7 years.
A thorough history and clinical examination were done and 
findings were recorded in predesigned pro forma. Liver function 
tests (LFTs) were done which included total bilirubin, liver 
enzymes (serum glutamic oxaloacetic transaminase [SGOT], 
serum glutamic pyruvic transaminase [SGPT], and alkaline 
phosphatase [ALP]), total protein, serum albumin, viral markers 
including hepatitis B surface antigen (HBsAg), and anti-HCV 
and serum ferritin level. The age of initiation of BT was also 
recorded. Derangement in LFTs and correlation between the 
age of initiation of transfusion therapy and derangement of liver 
function were studied.
Data were analyzed using statistical software MS Excel 
and SPSS for Windows. Data were reported as mean (SD) 
and proportions as deemed appropriate for quantitative and 
qualitative variables, respectively. Correlation between the age of 
initiation of transfusion therapy and derangement in LFTs was 
evaluated using Pearson correlation coefficient (r). Frequency 
and percentages were presented for qualitative variable.
RESULTS
The age-wise distribution of thalassemia patients is discussed in 
Table 1. The median age was 11.5 years.
In this study, majority of patients (75%) started receiving BT 
before the age of 1 year and 8 (25%) patients started after 1 year of 
age. However, we did not find any significant correlation between 
the age of initiation of BT and derangement of liver enzymes. In 
this study, males (18, 56.25%) were more in number than females 
(14, 43.75%).
The values of the LFTs in thalassemic patients are given in 
Table 2. The mean SGOT, SGPT, and serum bilirubin levels were 
70.9±23.4 U/L, 60.8±18.1 U/L, and 1.91±0.08 mg/dL, respectively. 
The mean total protein and serum albumin were 6.28±0.72 and 
3.27±0.35 g/dL, respectively. Significant derangement in liver 
enzymes was taken as twice the upper limit of reference range. 
Only two patients had significantly deranged LFT and one of 
these patients was anti-HCV positive and another had chronic 
anemia due to irregular BT therapy. There was no HBV-positive 
patient in our study. All the patients had received hepatitis B 
vaccine before the start of transfusion therapy.
The serum ferritin levels of thalassemic patients are discussed 
in Table 3. Majority of the patients (43.75%) had serum 
ferritin level between 2000 and 2999 ng/ml and the mean was 
2176±868 ng/ml (range: 268–4368 ng/ml). Out of 32 patients, 
29 patients (90.62%) were on regular chelation therapy.
DISCUSSION
Derangement in liver function is common in thalassemic patients 
receiving multiple BTs which are mainly due to iron deposition 
in liver and hepatitis. With regular iron chelation treatment, the 
degree of iron overload is reduced in most of our patients as also 
seen in other studies. In this study, 25 patients (78.12%) had 
deranged liver function. Significant increase in enzymes levels 
was seen in only 2 (6.25%) patients. Majority (43.75%) of the 
patients had ferritin value between 2000 and 2999 ng/ml and most 
of the patients (90.62%) were on chelation therapy.
In a study conducted by Singh et al., SGOT, SGPT, and ALP 
were found to be increased in 80%, 45%, and 87% of the patients, 
respectively [7]. Significant derangements of these enzymes were 
seen in 34%, 19%, and 9% patients, respectively. HBV and HCV 
were positive in 1% and 12% and serum total protein and albumin 
were low in 22% and 23% of patients, respectively. Serum 
bilirubin was increased in 53% of the patients. Majority (28%) 
of the patients had ferritin value between 2001 and 3000 ng/ml.
The results in our study were in accordance with another 
study conducted by Ayyash and Sirdah, where liver function was 
significantly deranged in thalassemic patients [8]. However, the 
mean serum ferritin levels were higher than that of our study. 
In another study conducted by Williams et al., the prevalence 
of HCV among thalassemic patients was 11.1% and 66.6% of 
patients showed evidence of HBV infection [9]. In another study 
conducted by Salama et al., none of the patient tested positive for 
HBV, but 50% of patients was anti-HCV positive [10]. Similarly, 
24% of patients were tested positive for anti-HCV in a study 
conducted by Agrawal et al. [11]. This is in contrast to this study, 
in which no patient was HBsAg positive and only one patient was 
anti-HCV positive.
If thalassemic patients are given properly tested blood and 
regular chelation therapy, their liver function remains normal. 
Although mild derangement in liver function can be present due 
to multiple BTs, significant damage to liver can be controlled. 
In hepatitis seronegative thalassemic patients, regular BT along 
Table 1: Age-wise distribution of thalassemia patients
Age group (years) Number of patients Percentage
1–5 8 25
6–10 7 21.87
11–15 15 46.87
>15 2 6.25
Total 32 100
Table 2: Liver function tests in thalassemic patients
Liver 
function tests
Serum 
bilirubin (%)
Serum glutamic oxaloacetic 
transaminase (%)
Serum glutamic pyruvic 
transaminase (%)
Alkaline 
phosphatase (%)
Total 
protein (%)
Serum 
albumin (%)
Normal value 7 (21.87) 15 (46.87) 17 (53.12) 8 (25) 27 (84.37) 29 (90.62)
Abnormal 
value
25 (78.12) 17 (53.12) 15 (46.87) 24 (75) 5 (15.62) 3 (9.37)
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with iron chelation therapy helps in maintaining liver function 
and decreasing iron overload in liver. It is recommended that 
immunization against hepatitis B and strict testing of blood bags at 
blood banks for hepatitis C must be done. It is also recommended 
that LFT should be repeated regularly at 3 months interval to 
detect any hepatic dysfunction.
CONCLUSION
In hepatitis seronegative thalassemic patients, regular BT along 
with iron chelation therapy helps in maintaining liver function 
and decreasing iron overload in liver. It is also recommended that 
LFT should be done regularly at 3 months interval to detect any 
hepatic dysfunction.
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